查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1178007

干癣性关节炎治疗药的全球市场:产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)

Psoriatic Arthritis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

本报告提供全球干癣性关节炎治疗药市场相关调查分析，提供市场促进因素和阻碍因素，机会，主要的考察，各市场区隔的分析与预测，各地区分析，企业简介等资讯。

目录

第1章 序文

第2章 前提与调查手法

第3章 摘要整理:全球干癣性关节炎治疗药市场

第4章 市场概要

  • 简介
    • 市场区隔定义
  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 全球干癣性关节炎治疗药市场分析与预测(2017年～2031年)
    • 市场收益预测
    • 市场规模·出货台数预测
  • 波特的五力分析

第5章 主要考察

  • 全球主要国家的疾病的盛行率·发病率
  • 开发平台分析
  • 主要的合併和收购
  • COVID-19影响分析

第6章 全球干癣性关节炎治疗药市场分析与预测:医药品分类

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测:医药品分类(2017年～2031年)
    • TNF抑制剂
    • 白细胞介素抑制剂
    • PDE4抑制剂
    • 其他
  • 市场魅力度分析:医药品分类

第7章 全球干癣性关节炎治疗药市场分析与预测:各给药途径

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测:各给药途径(2017年～2031年)
    • 口服
    • 非口服
    • 局部
  • 市场魅力度分析:各给药途径

第8章 全球干癣性关节炎治疗药市场分析与预测:各流通管道

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测:各流通管道(2017年～2031年)
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场魅力度分析:各流通管道

第9章 全球干癣性关节炎治疗药市场分析与预测:各地区

  • 主要调查结果
  • 市场价值预测:各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 市场魅力度分析:各地区

第10章 北美的干癣性关节炎治疗药市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测(2017年～2031年):医药品分类
    • TNF抑制剂
    • 白细胞介素抑制剂
    • PDE4抑制剂
    • 其他
  • 市场价值预测(2017年～2031年):各给药途径
    • 口服
    • 非口服
    • 局部
  • 市场价值预测(2017年～2031年):各流通管道
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:各国(2017年～2031年)
    • 美国
    • 加拿大
  • 市场魅力度分析
    • 医药品分类
    • 各给药途径
    • 各流通管道
    • 各国

第11章 欧洲的干癣性关节炎治疗药市场分析与预测

第12章 亚太地区的干癣性关节炎治疗药市场分析与预测

第13章 南美的干癣性关节炎治疗药市场分析与预测

第14章 中东·非洲的干癣性关节炎治疗药市场分析与预测

第15章 竞争情形

  • 市场参与企业 - 竞争矩阵(各等级及各规模企业)
  • 市场占有率分析:各企业(2021年)
  • 企业简介
    • AbbVie, Inc.
    • Janssen Pharmaceutical NV
    • Novartis AG
    • Amgen, Inc.
    • Celgene Corporation
    • Eli Lilly and Company
    • UCB SA
    • Bristol Myers Squibb
    • 其他的有名企业
Product Code: TMRGL61917

TMR's report on the global psoriatic arthritis therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global psoriatic arthritis therapeutics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global psoriatic arthritis therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the psoriatic arthritis therapeutics market.

The report delves into the competitive landscape of the global psoriatic arthritis therapeutics market. Key players operating in the global psoriatic arthritis therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global psoriatic arthritis therapeutics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriatic Arthritis Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Pipeline Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. Covid-19 Impact Analysis

6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. TNF Inhibitors
    • 6.3.2. Interleukin Inhibitors
    • 6.3.3. PDE4 Inhibitors
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. TNF Inhibitors
    • 10.2.2. Interleukin Inhibitors
    • 10.2.3. PDE4 Inhibitors
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. TNF Inhibitors
    • 11.2.2. Interleukin Inhibitors
    • 11.2.3. PDE4 Inhibitors
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
    • 11.3.3. Topical
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. TNF Inhibitors
    • 12.2.2. Interleukin Inhibitors
    • 12.2.3. PDE4 Inhibitors
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
    • 12.3.3. Topical
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. TNF Inhibitors
    • 13.2.2. Interleukin Inhibitors
    • 13.2.3. PDE4 Inhibitors
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
    • 13.3.3. Topical
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. TNF Inhibitors
    • 14.2.2. Interleukin Inhibitors
    • 14.2.3. PDE4 Inhibitors
    • 14.2.4. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
    • 14.3.3. Topical
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. AbbVie, Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Janssen Pharmaceutical NV
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Amgen, Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Celgene Corporation
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Eli Lilly and Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. UCB S.A
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bristol Myers Squibb
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Other Prominent Players

List of Tables

  • Table 01: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Psoriatic Arthritis Therapeutics Market Snapshot
  • Figure 02: Global Psoriatic Arthritis Therapeutics Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031
  • Figure 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 05: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration (2021)
  • Figure 06: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2021)
  • Figure 04: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class (2021)
  • Figure 07: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Region (2021)
  • Figure 08: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 09: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 10: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2021-2031
  • Figure 11: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2021-2031
  • Figure 12: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2021-2031
  • Figure 13: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021-2031
  • Figure 14: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 15: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 16: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2021-2031
  • Figure 17: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2021-2031
  • Figure 18: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2021-2031
  • Figure 19: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2031
  • Figure 20: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2021-2031
  • Figure 21: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2021-2031
  • Figure 22: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2021-2031
  • Figure 23: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 24: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region, 2017 and 2031
  • Figure 25: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 26: North America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 27: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country, 2017 and 2031
  • Figure 28: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 29: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 30: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 31: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 32: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 33: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 34: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 35: Europe Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 36: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 37: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 38: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 39: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 40: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 41: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 42: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 43: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 44: Asia Pacific Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 45: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 46: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 47: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 48: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 49: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 50: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 51: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 52: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 53: Latin America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 54: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 55: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 56: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 57: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 58: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 59: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 60: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 61: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 62: Middle East & Africa Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 63: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 64: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 65: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 66: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by drug Class, 2022-2031
  • Figure 67: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 68: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 69: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 70: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 71: Global Psoriatic Arthritis Therapeutics Market Share Analysis, by Company (2021)